Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lucia Lisi, Marta Chiavari, Gabriella Maria Pia Ciotti, Pedro M. Lacal, Pierluigi Navarra & Grazia Graziani. (2020) DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism & Toxicology 16:3, pages 195-207.
Read now
Read now
Qing Ya Wang, Yuan Li, Ze Yin Liang, Yue Yin, Wei Liu, Qian Wang, Yu Jun Dong, Yu Hua Sun, Wei Lin Xu & Han Yun Ren. (2019) Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease. Cancer Management and Research 11, pages 10195-10203.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now
Read now
Articles from other publishers (26)
Xiwen Tong, Mengyuan Li, Jie Jin, Yi Li, Li Li, Yizhou Peng, Lifang Huang, Bin Xu, Fankai Meng, Xia Mao, Liang Huang, Wei Huang & Donghua Zhang. (2023) Cladribine‐ and decitabine‐containing conditioning regimen has a low post‐transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. International Journal of Cancer 152:10, pages 2123-2133.
Crossref
Crossref
Yu-Hsin Chu, Yi-Chen Huang, Pei-Yun Chiu, Wen-Hung Kuo, Yan-Ru Pan, Yuan-Ting Kuo, Rong-Hsuan Wang, Yu-Chin Kao, Yi-Hsiang Wang, Yi-Fan Lin & Kai-Ti Lin. (2023) Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid. iScience 26:5, pages 106597.
Crossref
Crossref
Joana Alpoim-Moreira, Anna Szóstek-Mioduchowska, Magda Słyszewska, Maria Rosa Rebordão, Dariusz J. Skarzynski & Graça Ferreira-Dias. (2023) 5-Aza-2′-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts. Animals 13:7, pages 1212.
Crossref
Crossref
Ganjun Yu, Wenying Wang, Xiaobo He, Jia Xu, Rongrong Xu, Tao Wan & Yanfeng Wu. (2022) Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability. Frontiers in Oncology 12.
Crossref
Crossref
Zhenjie Zhuang, Xiaoying Zhong, Qianying Chen, Huiqi Chen & Zhanhua Liu. (2022) Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19. Frontiers in Pharmacology 13.
Crossref
Crossref
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han & Wenbin Qian. (2022) Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials. Cancer Communications 42:6, pages 493-516.
Crossref
Crossref
Donghao ShangGang LiCaixing ZhangYuting Liu. (2022) Synergistic inhibitory effects of 5-aza-2′-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways. Biochemistry and Cell Biology 100:2, pages 115-124.
Crossref
Crossref
Qing Ya Wang, Hui Hui Liu, Yu Jun Dong, Ze Yin Liang, Yue Yin, Wei Liu, Qing Yun Wang, Qian Wang, Yu Hua Sun, Wei Lin Xu, Na Han, Yuan Li & Han Yun Ren. (2022) Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Versus-Host Disease With Less Side Effects Through Altering T-Cell Differentiation. Frontiers in Immunology 13.
Crossref
Crossref
Chunhong Hu, Xiaohan Liu, Yue Zeng, Junqi Liu & Fang Wu. (2021) DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clinical Epigenetics 13:1.
Crossref
Crossref
Thoria Donia, Sherien Khedr, Elsayed I. Salim & Mohamed Hessien. (2021) Trichostatin A sensitizes hepatoma cells to Taxol more than 5-Aza-dC and dexamethasone. Drug Metabolism and Personalized Therapy 36:4, pages 299-309.
Crossref
Crossref
Amr El-Sayed, Lotfi Aleya & Mohamed Kamel. (2021) Microbiota and epigenetics: promising therapeutic approaches?. Environmental Science and Pollution Research 28:36, pages 49343-49361.
Crossref
Crossref
Thoria Donia, Sherien Khedr, Elsayed I. Salim & Mohamed Hessien. (2021) Trichostatin A sensitizes hepatoma cells to Taxol more than 5-Aza-dC and dexamethasone. Drug Metabolism and Personalized Therapy 0:0.
Crossref
Crossref
Xiang Li, Liang Dong, Jiejie Liu, Chunmeng Wang, Yan Zhang, Qian Mei, Weidong Han, Ping Xie & Jing Nie. (2021) Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Kah Keng Wong. (2020) DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications. Cellular Oncology 43:5, pages 779-792.
Crossref
Crossref
Xiaojuan Shi, Xinfeng Chen, Baijun Fang, Yu Ping, Guohui Qin, Dongli Yue, Feng Li, Shengli Yang & Yi Zhang. (2019) Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma. Biomedicine & Pharmacotherapy 112, pages 108632.
Crossref
Crossref
Khushboo Agrawal, Viswanath Das, Natálie Táborská, Ján Gurský, Petr Džubák & Marián Hajdúch. (2018) Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs. Stem Cells International 2018, pages 1-11.
Crossref
Crossref
Zhong‑Tian Bai, Bing Bai, Jun Zhu, Cui‑Xia Di, Xun Li & Wen‑Ce Zhou. (2017) Epigenetic actions of environmental factors and promising drugs for cancer therapy (Review). Oncology Letters.
Crossref
Crossref
Jihao Zhou, Yushi Yao, Qi Shen, Guoqiang Li, Lina Hu & Xinyou Zhang. (2017) Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. Journal of Cancer Research and Clinical Oncology 143:8, pages 1371-1380.
Crossref
Crossref
Alessandra Fragale, Giulia Romagnoli, Valerio Licursi, Maria Buoncervello, Giorgia Del Vecchio, Caterina Giuliani, Stefania Parlato, Celeste Leone, Marta De Angelis, Irene Canini, Elena Toschi, Filippo Belardelli, Rodolfo Negri, Imerio Capone, Carlo Presutti & Lucia Gabriele. (2017) Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells. Cancer Immunology Research 5:7, pages 604-616.
Crossref
Crossref
Michael KlutsteinJoshua Moss, Tommy Kaplan & Howard Cedar. (2017) Contribution of epigenetic mechanisms to variation in cancer risk among tissues. Proceedings of the National Academy of Sciences 114:9, pages 2230-2234.
Crossref
Crossref
Valeria Lucarini, Carla Buccione, Giovanna Ziccheddu, Francesca Peschiaroli, Paola Sestili, Rossella Puglisi, Gianfranco Mattia, Cristiana Zanetti, Isabella Parolini, Laura Bracci, Iole Macchia, Alessandra Rossi, Maria Teresa D'Urso, Daniele Macchia, Massimo Spada, Adele De Ninno, Annamaria Gerardino, Pamela Mozetic, Marcella Trombetta, Alberto Rainer, Luca Businaro, Giovanna Schiavoni & Fabrizio Mattei. (2017) Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. Journal of Investigative Dermatology 137:1, pages 159-169.
Crossref
Crossref
Chunchao Zhang, Jinfeng Suo, Hiroyuki Katayama, Yue Wei, Guillermo Garcia-Manero & Samir Hanash. (2016) Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clinical Proteomics 13:1.
Crossref
Crossref
Ana Carolina Morandini, Carlos F. Santos & Özlem Yilmaz. (2016) Role of epigenetics in modulation of immune response at the junction of host–pathogen interaction and danger molecule signaling. Pathogens and Disease 74:7, pages ftw082.
Crossref
Crossref
Lin Liu, Lin Chen, Xuan Wu, Xiang Li, Yang Song, Qian Mei, Jing Nie & Weidong Han. (2016) Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497. Journal of Cancer Research and Clinical Oncology 142:7, pages 1431-1439.
Crossref
Crossref
Jing Nie, Yan Zhang, Xiang Li, Meixia Chen, Chuanjie Liu & Weidong Han. (2016) DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire. Oncotarget 7:25, pages 37882-37892.
Crossref
Crossref
Lei Wang, Zohreh Amoozgar, Jing Huang, Mohammad H. Saleh, Deyin Xing, Sandra Orsulic & Michael S. Goldberg. (2015) Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunology Research 3:9, pages 1030-1041.
Crossref
Crossref